Aman, J, Duijvelaar, E, Botros, L, Kianzad, A, Schippers, J, Smeele, P, Azhang, S, Bartelink, I, Bet, P, Boersma, W, Boomars, K, Bonta, P, Bos, L, Van Bragt, J, Braunstahl, G-J, Celant, L, Eger, K, Geelhoed, M, Van Glabbeek, Y, Grotjohan, H, Hagens, L, Happe, C, Heunks, L, Van Den Heuvel, M, Hoefsloot, W, Hoek, R, Hoekstra, R, Hofstee, H, Vanhove, A, Juffermans, N, Lammers, M, Kos, R, Kemper, M, Kunst, P, Van Der Lee, I, Van Der Lee, L, Mau-Asam, P, Maitland-Van Der Zee, A-H, Mieras, A, Nossent, E, Overbeek, M, Oswald, L, Paternotte, N, Pamplona, C, Pronk, N, De Raaf, M, Slob, E, Neto, A S, Schultz, M, Smit, M, Smeenk, F, Smits, J, Stalenhoef, J, Tuinman, P R, Wessels, J, Van Wezenbeek, J, Noordegraaf, A V, Handoko-De Man, F & Bogaard, H J 2021, ' Late Breaking Abstract-A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 ', European Respiratory Journal, vol. 58 . https://doi.org/10.1183/13993003.congress-2021.OA4119 European Respiratory Journal Airway cell biology and immunopathology European Respiratory Journal, 58. European Respiratory Society
lancet. Respiratory medicine, 9(9), 957-968. Elsevier Limited The Lancet Respiratory Medicine, 9(9), 957-968. ELSEVIER SCI LTD The Lancet Respiratory Medicine, 9(9), 957-968. Elsevier Ltd. Lancet Respiratory Medicine, 9, 957-968 Aman, J, Duijvelaar, E, Botros, L, Kianzad, A, Schippers, J R, Smeele, P J, Azhang, S, Bartelink, I H, Bayoumy, A A, Bet, P M, Boersma, W, Bonta, P I, Boomars, K A T, Bos, L D J, van Bragt, J J M H, Braunstahl, G-J, Celant, L R, Eger, K A B, Geelhoed, J J M, van Glabbeek, Y L E, Grotjohan, H P, Hagens, L A, Happe, C M, Hazes, B D, Heunks, L M A, van den Heuvel, M, Hoefsloot, W, Hoek, R J A, Hoekstra, R, Hofstee, H M A, Juffermans, N P, Kemper, E M, Kos, R, Kunst, P W A, Lammers, A, van der Lee, I, van der Lee, E L, Maitland-van der Zee, A-H, Mau Asam, P F M, Mieras, A, Muller, M, Neefjes, L, Nossent, E J, Oswald, L M A, Overbeek, M J, Pamplona, C, Paternotte, N, Pronk, N, de Raaf, M A, van Raaij, B F M, Reijrink, M, Schultz, M J, Serpa Neto, A, Slob, E M, Smeenk, F W J M, Smit, M R, Smits, A J, Stalenhoef, J E, Tuinman, P R, Vanhove, A L E M, Wessels, J N, van Wezenbeek, J C C, Vonk Noordegraaf, A, de Man, F S & Bogaard, H J 2021, ' Imatinib in patients with severe COVID-19 : a randomised, double-blind, placebo-controlled, clinical trial ', Lancet respiratory medicine, vol. 9, no. 9, pp. 957-968 . https://doi.org/10.1016/S2213-2600(21)00237-X The Lancet. Respiratory Medicine Lancet respiratory medicine, 9(9), 957-968. Elsevier Limited Lancet Respiratory Medicine, 9, 9, pp. 957-968 The Lancet Respiratory Medicine
Journal of Allergy and Clinical Immunology: In Practice, 10(7). American Academy of Allergy, Asthma and Immunology Journal of Allergy and Clinical Immunology: In Practice, 10(7) Eger, K, Kroes, J A, ten Brinke, A & Bel, E H 2022, ' Reply to “Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma” ', Journal of Allergy and Clinical Immunology: In Practice, vol. 10, no. 7, pp. 1936 . https://doi.org/10.1016/j.jaip.2022.04.018 Journal of Allergy and Clinical Immunology: In Practice, 10(7). Elsevier